+39 02 610346.1 - info@newron.com

Xadago® (safinamide)

Xadago® (safinamide)

First New Chemical Entity Approved in Europe and the U.S. for Parkinson’s Disease in a Decade

Xadago® (safinamide) is a New Chemical Entity for the treatment of Parkinson’s Disease with a mode of action characterized by selective MAO-B-inhibition. Results from two double-blind, placebo-controlled, multinational, 6 month studies with over 1,100 patients revealed that safinamide provides statistically significant increases in ON-time without troublesome dyskinesia, as well as a decrease in OFF-time. Safinamide requires a once-daily dose and has no diet restrictions due to its high MAO-B versus MAO-A selectivity. 

Borgohain R, et al. (2014) Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord, 29: 229–237.

Schapira A, Fox S, Hauser R, et al. (2016) Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations. A randomized clinical trial. JAMA Neurology 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467